-
EP4245305
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4245305
| EP4245305 - MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)]AND COMPOSITIONS THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 18.10.2024 Database last updated on 18.11.2024 | |
| Former | Request for examination was made Status updated on 05.04.2024 | ||
| Former | The application has been published Status updated on 18.08.2023 | Most recent event Tooltip | 19.10.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Bold Therapeutics Inc. 850 West Hastings Street, Suite 515 Vancouver, BC, V6C 1E1 / CA | [2023/38] | Inventor(s) | 01 /
VOJKOVSKY, Tomas Palm Beach Gardens, 33418 / US | 02 /
SILL, Kevin Tampa, 33647 / US | 03 /
CARIE, Adam Tampa, 33619 / US | [2023/38] | Representative(s) | Tostmann, Holger Carl Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte Partnerschaft mbB Zweibrückenstrasse 5-7 80331 München / DE | [2023/38] | Application number, filing date | 23186755.7 | 07.05.2018 | [2023/38] | Priority number, date | US201762501984P | 05.05.2017 Original published format: US 201762501984 P | [2023/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4245305 | Date: | 20.09.2023 | Language: | EN | [2023/38] | Type: | A3 Search report | No.: | EP4245305 | Date: | 04.10.2023 | Language: | EN | [2023/40] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 05.09.2023 | Classification | IPC: | C07F15/00, A61K31/416, A61K31/555, A61K33/24, A61P35/02, A61K9/19, A61K47/12, A61K47/26, A61K9/00, A61K33/243 | [2023/40] | CPC: |
C07F15/0053 (EP,CN,US);
A61K31/555 (CN);
A61K33/24 (EP,US);
A61K33/243 (EP,US);
A61K47/12 (EP,US);
A61K47/26 (EP,US);
A61K9/0019 (EP,US);
A61K9/19 (EP,US);
A61P35/00 (CN);
A61P35/02 (EP,US)
(-)
|
| Former IPC [2023/38] | A61K33/243 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/19] |
| Former [2023/38] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | HERSTELLUNG VON TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENAT(III)] UND ZUSAMMENSETZUNGEN DAVON | [2023/38] | English: | MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)]AND COMPOSITIONS THEREOF | [2023/38] | French: | FABRICATION DE TRANS-[TÉTRACHLOROBIS(1H-INDAZOLE)RUTHÉNATE (III)]ET COMPOSITIONS DE CEUX-CI | [2023/38] | Examination procedure | 04.04.2024 | Amendment by applicant (claims and/or description) | 04.04.2024 | Examination requested [2024/19] | 04.04.2024 | Date on which the examining division has become responsible | 18.10.2024 | Despatch of a communication from the examining division (Time limit: M04) | Parent application(s) Tooltip | EP18794220.6 / EP3618827 | Fees paid | Renewal fee | 20.07.2023 | Renewal fee patent year 03 | 20.07.2023 | Renewal fee patent year 04 | 20.07.2023 | Renewal fee patent year 05 | 20.07.2023 | Renewal fee patent year 06 | 17.05.2024 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [AD]WO2008154553 (NIIKI PHARMA INC [US], et al) | by applicant | US8362266 |